Meeting the demand for clinically relevant neurodegenerative treatments requires a paradigm shift in how central nervous system (CNS) clinical trials have been designed and executed.
Eisai and Biogen have moved swiftly ahead with regulatory filings for their new Alzheimer's therapy lecanemab in the EU, after getting a green light for the anti-amyloid beta antibody in th
Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug fr
With the FDA due to deliver a decision of Eisai and Biogen's new Alzheimer's disease candidate lecanemab tomorrow, the safety of the drug has been thrust into the spotlight by a case report
One of the most highly-anticipated developments in pharma next year will be the FDA's verdict on Eisai's accelerated application for lecanemab in Alzheimer's disease, due early in January.<
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl